Clinical Trial Update: Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a cancer peptide vaccine with GM-CSF as adjuvant therapy for high-risk or metastatic breast cancer with no evidence of disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cancer peptide vaccine (peptide vaccine)
• sargramostim (sargramostim)

Snippet

Sponsor: Duke University | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED